FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 354:785-788 February 23, 2006 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Interview Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The Centers for Disease Control and Prevention (CDC) recently issued an alert instructing clinicians to avoid using M2 ion-channel inhibitors (amantadine and rimantadine) during the current influenza season because amantadine resistance has been detected at an extraordinarily high frequency in isolates of influenza A (H3N2) virus (see table).^1,2,3 This and other reports⁴ raise important questions regarding the implications of resistance to antiviral agents for the current clinical management of influenza and for planning for a possible pandemic.

View this table:   Incidence of M2-Inhibitor Resistance among Human Influenza A (H3N2) Viruses in the United States.

 
Phenotypic amantadine resistance was first described soon after . . . [Full Text of this Article]

Source Information

Dr. Hayden is a professor of internal medicine and pathology in the Division of Infectious Diseases and International Health, Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville.

An interview with Dr. Hayden can be heard at www.nejm.org.

This article has been cited by other articles:

• Yamashita, M., Tomozawa, T., Kakuta, M., Tokumitsu, A., Nasu, H., Kubo, S. (2009). CS-8958, a Prodrug of the New Neuraminidase Inhibitor R-125489, Shows Long-Acting Anti-Influenza Virus Activity. Antimicrob. Agents Chemother. 53: 186-192 [Abstract] [Full Text]  
• Ilyushina, N. A., Hay, A., Yilmaz, N., Boon, A. C. M., Webster, R. G., Govorkova, E. A. (2008). Oseltamivir-Ribavirin Combination Therapy for Highly Pathogenic H5N1 Influenza Virus Infection in Mice. Antimicrob. Agents Chemother. 52: 3889-3897 [Abstract] [Full Text]  
• Dimmock, N. J., Rainsford, E. W., Scott, P. D., Marriott, A. C. (2008). Influenza Virus Protecting RNA: an Effective Prophylactic and Therapeutic Antiviral. J. Virol. 82: 8570-8578 [Abstract] [Full Text]  
• Rubinson, L., Hick, J. L., Hanfling, D. G., Devereaux, A. V., Dichter, J. R., Christian, M. D., Talmor, D., Medina, J., Curtis, J. R., Geiling, J. A. (2008). Definitive Care for the Critically Ill During a Disaster: A Framework for Optimizing Critical Care Surge Capacity: From a Task Force for Mass Critical Care Summit Meeting, January 26-27, 2007, Chicago, IL. Chest 133: 18S-31S [Abstract] [Full Text]  
• Rubinson, L., Christian, M. D. (2008). Allocating Mechanical Ventilators During Mass Respiratory Failure: Kudos to New York State, but More Work to Be Done. dmphp 2: 7-10 [Full Text]  
• Yen, H.-L., Ilyushina, N. A., Salomon, R., Hoffmann, E., Webster, R. G., Govorkova, E. A. (2007). Neuraminidase Inhibitor-Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication Efficiency and Pathogenicity In Vitro and In Vivo. J. Virol. 81: 12418-12426 [Abstract] [Full Text]  
• Simonsen, L., Viboud, C., Grenfell, B. T., Dushoff, J., Jennings, L., Smit, M., Macken, C., Hata, M., Gog, J., Miller, M. A., Holmes, E. C. (2007). The Genesis and Spread of Reassortment Human Influenza A/H3N2 Viruses Conferring Adamantane Resistance. Mol Biol Evol 24: 1811-1820 [Abstract] [Full Text]  
• Committee on Infectious Diseases, (2007). Antiviral Therapy and Prophylaxis for Influenza in Children. Pediatrics 119: 852-860 [Abstract] [Full Text]  
• Weinstock, D. M., Zucotti, G. (2006). Shift Shown in Influenza A Adamantane Resistance--Reply. JAMA 296: 1587-1587 [Full Text]